UK markets closed

Basilea Pharmaceutica AG (0QNA.L)

LSE - LSE Delayed price. Currency in CHF
Add to watchlist
48.90-0.10 (-0.21%)
At close: 05:41PM GMT
Full screen
Previous close49.00
Open48.45
Bid0.00 x 0
Ask0.00 x 0
Day's range48.45 - 49.60
52-week range48.45 - 49.60
Volume2,325
Avg. volumeN/A
Market cap5.276M
Beta (5Y monthly)0.87
PE ratio (TTM)N/A
EPS (TTM)-0.58
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Globe Newswire

    Basilea reports preliminary operating profit for 2022, significantly above guidance

    Successful implementation of strategic decision to focus on anti-infectives and stronger than expected revenue lead to profitability earlier than anticipated Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, January 24, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial or fungal infections, announced today that on an unaudited preliminary basis it expects to have achieve

  • Globe Newswire

    Basilea reports preliminary 2022 revenues, exceeding guidance, and provides portfolio update

    Continued commercial success of Cresemba and Zevtera in 2022 generated revenue contributions of approx. CHF 122 million, exceeding guidance by more than 17%Significant proceeds from oncology transactionsFollowing pre-NDA (New Drug Application) meeting held with FDA in Q4 2022 for ceftobiprole (Zevtera), NDA submission for three indications planned within two to three monthsBuilding a balanced R&D portfolio of antibacterial and antifungal drug candidates to support sustainable long-term growth in

  • Globe Newswire

    Continued strong Cresemba® (isavuconazole) sales by Astellas in the U.S. trigger CHF 20 million sales milestone payment to Basilea

    Ad hoc announcement pursuant to Art. 53 LR Basel/Allschwil, Switzerland, January 09, 2023 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of patients with severe bacterial and fungal infections, announced today that the continued strong sales of the antifungal Cresemba® (isavuconazole) achieved by its partner Astellas Pharma Inc. (“Astellas”) in the United States in 2022 exceeded the threshold triggering a milestone payment of CH